Arthur Tzianabos Sells 4,355 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Arthur Tzianabos sold 4,355 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total transaction of $174,200.00. Following the sale, the insider owned 31,339 shares of the company’s stock, valued at $1,253,560. This trade represents a 12.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $33.19 on Friday. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of 49.54 and a beta of 1.07. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $40.22. The firm’s 50-day simple moving average is $32.71 and its two-hundred day simple moving average is $29.56.

Institutional Trading of Stoke Therapeutics

Institutional investors have recently modified their holdings of the business. Invesco Ltd. boosted its holdings in Stoke Therapeutics by 24.7% in the 4th quarter. Invesco Ltd. now owns 259,543 shares of the company’s stock worth $8,238,000 after buying an additional 51,468 shares during the period. NewEdge Advisors LLC bought a new stake in Stoke Therapeutics during the 4th quarter valued at $330,000. Tudor Investment Corp ET AL purchased a new stake in shares of Stoke Therapeutics during the fourth quarter worth $613,000. Readystate Asset Management LP purchased a new stake in shares of Stoke Therapeutics during the fourth quarter worth $922,000. Finally, RTW Investments LP boosted its holdings in shares of Stoke Therapeutics by 8.3% in the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after acquiring an additional 423,331 shares during the period.

Analyst Ratings Changes

Several equities analysts recently commented on the company. UBS Group set a $50.00 price objective on Stoke Therapeutics in a research note on Monday, December 15th. Guggenheim started coverage on Stoke Therapeutics in a research report on Thursday, February 5th. They issued a “buy” rating and a $60.00 target price for the company. HC Wainwright boosted their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Canaccord Genuity Group upped their price target on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Finally, Loop Capital set a $35.00 price target on Stoke Therapeutics in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $39.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.